Prolymphocytic teukemia (PLL] is a chronic lymphoproliferative disorder, characterized by prominent splenomegaly, prolymphocytes accounting for more than 55% of circulating lymphocytes, and short-term survival. To better characterize the nature of the cellular origin in this disease, we analyzed Ig heavy chain variable region (V,) genes in eleven cases of de novo PLL. Leukemic cells expressed a skewed repertoire characterized by predominant use of the V3 family members (73%). with preferential use of the V3-23 gene (50% of the VH3 genes). All sequences from expressed Vn genes diverged from their putative germline counterpart, and in eight cases ROLYMPHOCYTIC leukemia (PLL) is a relatively rare P form of chronic lymphoproliferative disease, first described by Galton in 1974.' According to French-AmericanBritish (FAB) diagnostic criteria, the hallmark of the disease is the presence of more than 55% circulating morphologically identified prolymphocytes.' It is a distinct clinicopathological entity characterized by massive splenomegaly without lymph node enlargement, frequent marked hyperleukocytosis (often >lo0 x 109/L; the majority of which are prolymphocytes), and associated anemia and thrombopenia. Morphologically, prolymphocytes are large cells with condensed nuclear chromatin and a prominent central nucleolus. The vast majority of PLL are from the B-lineage origin and express high density monotypic surface immunoglobulin (sIg), usually IgM with or without IgD, and the CD19, CD20, and CD22 B cell marker^.^ In contrast to chronic lymphocytic leukemia (CLL), they often express FMC7, but rarely CD23. About half of the cases express the CD5 antigen. Although PLL is considered to be distinct from CLL by many criteria, the delineation between the two is not clearcut because some cases of CLL can transform into PLL: Furthermore, mixed forms of CLLPL have been identified in which the number of prolymphocytes is between 10% and 55%.5
cytic leukemia (CLL), they often express FMC7, but rarely CD23. About half of the cases express the CD5 antigen. Although PLL is considered to be distinct from CLL by many criteria, the delineation between the two is not clearcut because some cases of CLL can transform into PLL: Furthermore, mixed forms of CLLPL have been identified in which the number of prolymphocytes is between 10% and 55%. 5 Analysis of Ig genes has provided important information in understanding the biology of B-cell tumors6 After completing a series of complex DNA rearrangements of the Ig genes in the bone marrow, virgin B cells emigrate to the lymphoid organs. Further maturation of B lymphocytes occurs within the germinal centers of these organs, including the introduction of point mutations in the Ig variable (V) regions by the poorly understood mechanism of somatic hypermutation.' On stimulation by local antigens, those cells expressing V genes with mutations leading to higher affinity are selected and expand preferentially. This process results in the generation of memory B cells and high-affinity antibody producing cells. Consequently point mutations are found preferentially in nucleotides coding for amino acid residues critical for antigen-antibody interactions, the complementarity determining regions (CDR). In contrast, polyclonal stimulation not mediated by antigen results in mutations that are randomly distributed throughout the V regions. 8 Analysis of V region nucleotide sequences can therefore In this study, we have analyzed nucleotide sequences of Ig heavy chain variable (V,) regions from 11 de novo PLL cases to determine at which stage of B-cell development the clonal expansion of leukemic cells occurs. Our results show that PLL represents, at least in some instances, an expansion of memory B cells. AmpliJcation of tumor cell variable region heavy chain genes. High molecular weight DNA was extracted from leukemic cells using standard procedure^.'^ Amplification of rearranged VH genes was performed in a two-step procedure. In the first step, 1 pg of genomic DNA was amplified with a 5' consensus primer designed to anneal to framework (FR) I of most VH genes except members of the VH2 family: AGGTGCAGCTGSWGSAGTCDGG, a vH2 family-specific primer: CAGGTCACC'ITGARGGAGTCTGG, and an external 3' consensus JH primer: ACCTGAGGAGACGGTGAC-CRKKGT. In the second step 2.5 pL (5%) of this first polymerase chain reaction (PCR) reaction was reamplified in six independent reactions using internal FR1 VH family-specific primers: VH1: TCG-GATCCTCRGTGARGGTYTCCTGC; vH2: GAAGATCTCAC~ CTGACCTGCACCKTC; vH3: GAAGATCTCTCFEECAGCC-TCTGG; VA: GAAGATCTGTCFFEECTGCRYTGT; vH5:
MATERIALS AND METHODS

Patients
C C A G A T C T C C T G T m ' I T C T G G ; VH6: GAAGATCTCTCA-CTCACCTGTGCCATC, and an internal JH consensus primer: TGGAATTCCAKGGTBCCTYGCCCAG (underlined sequences indicate restriction endonuclease sites). For each step, amplification consisted of 20 cycles (94°C for 45 seconds, 55°C for 45 seconds, and 72°C for 45 seconds) and was performed with Pfu Polymerase (Stratagene, La Jolla, CA). In one case, no PCR product could be obtained using this procedure and amplification was, therefore, performed using a 5' FR2 consensus oligonucleotide: TGGRTCCGV-CAGSCYCCNGG with the external JH consensus primer in a single step amplification (35 cycles of 94°C for 45 seconds, 60°C for 45 seconds, and 72°C for 45 seconds). In addition, in selected cases, VH gene amplification was performed using family-specific leader primers (LH) as previously described. '6 Amplified VH fragments from the two-step procedure were gel purified, digested with EcoRl and BamHI or BgZ I1 (BRL, Gaithersburg, MD) and ligated into the pGEM vector (Promega, Madison, WI). Ligation products were transfected into JM109 E coli competent cells. Alternatively PCR products from the FR2 and LH amplifications were cloned directly into the pCR-Script vector (Stratagene). Clones harboring recombinant plasmids with inserts of appropriate size, based on restriction analysis, were sequenced using the dideoxy chain termination method with T7 DNA Polymerase (Pharmacia, Uppsala, Sweden). All inserts were sequenced in both directions and from multiple independent clones from at least two PCR amplifications. Sequence analysis and comparisons were performed with the Genetics Computer Group, Inc (Madison, WI) software package and the Genebank (Los Alamos, NM) and EMBL (Heidelberg, Germany) databases.
Cloning and sequencing of PCR products.
RESULTS
Patients and PLL cells. Eleven patients with clinical and morphological features of de novo PLL were included in this study. The main phenotypic characteristics are listed in Table 1 . Lymphocytosis ranged from 9 X 109L to 720 X 109L. The proportion of prolymphocytes varied from 59% to 98%. Three cases expressed IgM only, five cases both IgM and IgD, one case IgG, and one case IgA. The Ig heavy chain (IgH) isotype was not determined in one case. As expected, high-density membrane sIg, as estimated by flow cytometry, was found in most cases (9 of 10). All cases tested expressed CD19 and FMC7. CD23 was detected in only two cases, and CD5 was present in six cases (55%). In all cases, two Ig heavy chain gene rearrangements were detected by Southern blot analysis (data not shown).
Fourteen different VH sequences were amplified by DNA PCR from the 11 patients studied. Deduced amino acid sequences are shown in Fig 1. Eleven of these sequences represented productive rearrangements (one for each patient), while nonproductive rearrangements were also obtained in three cases (PLL-lb, PLL-2b, and PLL-6b). These nonfunctional IgH genes were the results of out of frame rearrangements (PLL-lb, PLL-6b) or had stop codons in their CDR3 sequences (PLL-2b). Identification of the VH genes is shown in Table 2 . Of the productive rearrangements, a vH3 gene was found eight times and a vH4 gene three times. The V3-23 (VH26) gene was used with a surprisingly high incidence, as it constituted half of these eight vH3 genes and 36% of all productive rearrangements. The four other productive vH3 genes consisted of V3-14, V3-72, V3-48, and V3-7. The three other functional genes were members of the V& family and consisted of V4-34 (VH4.21) in two cases and V4-59 (VH4.1 1) in one case. One vH1 gene (Vl-2), one vH2 gene (VII-5), and one VH3 gene (V3-13) were used in the nonproductive rearrangements.
Presence of mutations in V , genes. Sequences were compared with those of the germline VH genes available in current databases (see Materials and Methods and Fig I) . Most sequences obtained diverged substantially from their closest germline counterparts, except for the nonproductive vH3 gene (PLL-2b; Table 2 ). The percentage homology varied from 86.7% to 99.6%, with only two sequences showing more than 98% homology. This divergence could be due to somatic mutation, polymorphism or to previously unidentified germline sequences. This latter explanation is unlikely since most, if not all VH germline genes have been identified.".l8 Polymorphism is well recognized in the case of the vH3 genes, which represent the largest VH family."' Many "mutations" detected in the PLL VH3 gene sequences might therefore correspond, in fact, to polymorphic variations. However, it should be noted that divergence from the germline sequence also extended to the D and JH gene segments (Fig 2) in some cases (PLL-5, 6a, 7, 9). Formal delineation of somatic mutations from polymorphic variations requires the isolation of the germline VH gene counterpart from nonleukemic cells. Because this material was not available in most of our PLL cases, the following approach was undertaken. (1) We restricted our analysis to the seven cases expressing either the V3-23 or the VH4 family genes, for which polymorphism has been studied In the case of the V3-23 gene, polymorphisms have been shown to result from either deletionhsertion of gene copies, or from sequence differences at endonuclease restriction sites in the gene's flanking regions, but not in the coding region itself.z2 Members of the VH4 family are known to display very little (2) We performed a computer analysis with over 1,500 Ig gene sequences deposited in databases (Genbank, EMBL, VBase). The original sequence and possi- ble polymorphic variants were aligned with those from our patients. As can be seen in the cases expressing the V3-23 gene, only a minority of substitutions observed in our patients corresponded to a known polymorphism (Fig 3) . In cases expressing a V& family gene, no nucleotide substitution could be assigned to polymorphic variation (data not shown). Furthermore, in several cases the divergence between PLL sequences and the germline counterpart was too important (>4%) to be accounted for polymorphism. Screening the Ig gene databases with short sequences derived from the various CDR and FR regions of our patients VH genes, identified the same germline counterparts and polymorphic variants, thus ruling out the possibility that some other germline homologue had been missed when using the whole VH sequence. (3) To further confirm the identity of the corresponding germline VH gene, we analyzed the leader (LH) intron sequence in the selected seven cases. These sequences are known to be specific for individual V genes and less somatically mutated than the coding regions." Using LH family-specific primers for PCR, we isolated clones carrying CDR3 sequences identical to those previously obtained with FR1 or FR2 primers. PLL-2a, 4, 6a, and 1 1 had intron sequence strictly identical to that of their corresponding germline gene, while PLL-3 and 9 had one nucleotide mismatch and PLLS two nucleotide mismatches (data not shown). Taken together, these results indicate that in these seven PLL cases, the putative germline VH gene counterpart had been correctly identified, and that most of the observed nucleotide substitutions could be attributed to somatic mutations with confidence. Of note, two of the three nonproductive genes (PLL-lb and 2b) were very close to their germline counterpart (98.4% and 99.6% homology, respectively), while one (PLL-6b) diverged substantially (95.6% homology). The role of antigenic selection can be deduced from the distribution of somatic mutations in V regions. Considering the respective length of CDRs and FRs, a random distribution of mutations should give a ratio of CDR to FR mutations of less than 0.3.27 When considering only the seven cases for which nucleotide substitutions could be attributed to somatic mutations with most certainty and excluding nucleotide substitutions possibly contributed by polymorphism, all had a CDR:FR ratio above 0.3, ranging from 0.6 to 2, indicating a nonrandom distribution of mutations (Table 2) . Furthermore, when analyzing the type of nucleotide substitutions, a random pattern of mutations gives a ratio of replacement (R) mutations to silent (S) mutations of 2.9 or less." In contrast, in cases undergoing antigenic selection, the R:S ratio is higher than 2.9 in the CDRs, whereas it is below this value in the FRs. As can be seen in Table 2 , five cases (PLL-3, 4, 5, 6a, and 1 1) had an R:S ratio equal to or above 3 in their CDR, while
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Distribution pattern of mututions.
this ratio was equal to or less than 2 in their FR. When applying a binomial m0de1,~"*~ the R:S ratio values in the CDRs reached significance ( P < .05) for only three cases (PLL-5, 6a, and 11) and was just above the threshold for one case (PLL-4) ( Table 3) . These results strongly suggest that in these cases, the leukemic cell progenitors had been subjected to an antigenic selection process. There were no clearcut differences in the frequency of mutations between cases expressing sIgM, sIgM and sIgD, sIgG, or sIgA. Similarly, a roughly equivalent number of mutations was found in CD5' and CD5.-cases.
Intracloital diversity. In each case studied, four to six sequences were obtained from independent PCR. Single point mutations were occasionally detected within different clones for the same patient, but with a low frequency ( I of 1,200). To determine whether this was due to intraclonal diversification or to nucleotide misincorporation by the Pfu polymerase, we performed an identical amplification and analysis of the VH genes in two cases of ALL which had previously been sequenced in our laboratory.'') Analysis of more than 6,000 base pairs showed only one nucleotide difference. It is, therefore, possible that the rare nucleotide differences observed in our cases of PLL might correspond to intraclonal diversity.
Analysis of JH genes (Fig 2) showed that four cases used a JH3 gene segment, four a JH4 gene segment, only one case a JH5 gene segment, and four a JH6 gene segment. In one case (PLL-1 a), the corresponding JH gene could not be identified because of extensive removal of its 5' region during the D to JH recombination. No preferential usage of D segment could be observed. As noted in a previous section, one or two point mutations were present in the D and JH segments for some patients. At least 50% of these CLL express germline VH genes, suggesting that they represent expansion of pregerminal center B cells. However, the rare CLL cases expressing IgG isotypes tend to use more frequently mutated VH genes, with evidence for antigen selection in some cases.3' Little is known about VH repertoire in PLL, in part, because of the relative rarity of the disease. Previous clinical, morphological and immunological studies have shown that it represents a separate entity.'.' However, it may bear some relationship with CLL, because the latter can transform into true PLL. 4,' In this study, we have analyzed Ig heavy chain gene sequences in 1 I cases of PLL. VH expression was characterized by a distinct overrepresentation of the largest vH3 family (73% of the productive rearrangements), and a clear underrepresentation of VH1 (7%), the second largest family. Similar findings have been reported in CD5-CLL.?* There was an obvious skewed use of individual VH3 genes, because one gene, V3-23, accounted for 50% of the expressed vH3 genes, and 37% of all productive IgH genes. Similarly, the v4-34 gene represented two of the three vH4 family genes expressed. Taken together, these two genes accounted for more than half of the PLL repertoire. They have been identified in auto antibodies with anti-DNA activity" (V3-23) and specificity for the erythroid I/i antiged4 (V4-34). They are ......... ..T ..........................................  .........................................................  .........................................................  ........................................................  ............ ..T .......................................... , 4GC TAT GCC ATG AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA .A. ......... G.. ..................... G.. .............. Pis the probability that the number of observed replacement mutations in the CDR would occur by chance alone. It was calculated using a binomial distribution m~d e l ? '~~~ In the case of PLL-9, no R mutation occurred in the CDR and, therefore, P refers to the occurrence of R mutation in the FR.
D and JH gene usage.
DISCUSSION
Analysis of Ig genes variable regions in B-cell tumors has provided important information on these cells, both in terms
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overrepresented in the fetal and adult normal repert0ires,3~-'~ as well as in lymphoid tumors such as CLL." The reasons for the overexpression of these genes remain unclear. Several explanations have been proposed, including the occurrence of several genomic copies, particular regulatory regions and selection through certain antigen binding or idiotypic determinants. In the case of the V3-23 gene, the fact that the same degree of overexpression has been observed in both productive and nonproductive rearrangements of normal B cells favors an intrinsic genetic mechanism.39 Analysis of JH gene usage showed not only predominant use of the JH4 and JH6 genes, as is commonly observed in normal adult B but also of the JH3 gene, a feature reminiscent of the fetal r e p e r t~i r e .~~ Apart from two nonproductive rearrangements, all PLL sequences analyzed here diverged substantially (> 2%) from their putative germline counterparts. Restricting our analysis to the cases where polymorphism could be ruled out with certainty, ie, the V3-23 and VH4 genes, this divergence could be attributed to somatic mutations. This conclusion is further strengthened by the detection of point mutations in the corresponding D and JH gene segments for some cases. In three and possibly four instances, there was clear evidence that
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From these mutations appeared to have been antigen selected, with an accumulation of R over S mutations in the CDRs. The very low rate of intraclonal heterogeneity indicates that the mutational machinery was still minimally active. A similar low rate of somatic diversification has been reported in cases of CLL,41.42 a disease classically known for its absence of intraclonal diversity, and is much lower than that observed in FL.'2*14 Overall these results show that the clonal expansion in PLL occurred in a progenitor cell that had already encountered an antigen. This pattern resembles that observed in some cases of IgG' CLL,31 of Burkitt's lymphoma43 (BL), and of monoclonal gammopathy of undetermined significance." It contrasts with FL where the tumor cells can still undergo important clonal evolution due to numerous ongoing somatic Of the seven cases of PLL expressing clearly mutated genes, three expressed surface IgM and IgD (PLL-3, 5, and 1 l), two IgM (PLL-4 and 9), one IgG (PLL-2), and one IgA (PLL-6). There is now good evidence that both normal and tumor IgM' B cells can be subjected to somatic mutations.41.43-47 More intriguing is the finding of mutations in the IgM+ IgD' cells, which correspond to a more immature population. Indeed, these cells, which represent the major B-cell subset in the peripheral blood, express Ig light chain VK genes with no or little mutation^.^' In keeping with this, a recent study on tonsillar B cells has shown that somatic mutations tend to appear when B cells lose their ~1gD.~' Similarly, we have shown in a previous study3* that IgM' IgD+ CLL express VH genes with a lower mutation rate than IgM+ CLL (1.9 % v 5.4%). There were, however, some exceptions as one IgM+ IgD+ case had a 4.6% rate of mutation. IgM+ IgD+ tumor cells with somatic mutations (up to 5%) have also been described in splenic lymphoma with villous lymphocyte^^^ and BL.43 All of these cases may therefore represent transformation of cells belonging to a rare normal B-cell population, in which the process of somatic mutations operates at an immature stage of development. Alternatively, the transformation event may result in aberrant IgD expression or in alteration of the isotype-switch process.
CD5+ B lymphocytes are postulated to constitute a separate B-cell lineage that predominates in early ontogeny, expresses a germline repertoire of Ig genes, and is mainly committed to secreting natural a n t i b~d i e s .~~ Analyses of individual cells from human germinal centers have shown that the majority of B cells from the mantle zone, which express CD5, display unmutated Ig genes, whereas germinal center B cells Ig genes are extensively m~tated.~'' Studies of CD5+ malignancies, namely CLL' O and MZL," are consistent with this pattern. CD5' CLL can, however, display mutated VH genes, and this seems to be related with sIg isotype expression since the mutation rate was found to be higher in IgM' and particularly IgG+ CLL than in IgM' IgD' CLL.31,32 About half of the PLL studied here did not express CD5 and the mutation rate in these cases was not significantly different from the CD5' cases. Our data, therefore, confirm that CD5 expression is not restricted to pregeminal center cells.
A recent study including six cases of PLL failed to detect any mutations in the V K sequences of these tumors." The reasons for this discrepancy with our results are not clear, although several cases have been reported in which the light chain V genes remained germline or minimally mutated, whereas the VH genes were mutated. These include several CLL,'6.4' a case of mixed cryoglob~linemia,~~ cells expressing autoantibodies to the acetylcholine receptor,s3 and a murine secondary immune response to influenza virus hemagg l~t i n i n .~~ It is, therefore, possible that in some situations the mutation machinery affects heavy and light chain genes independently, or that certain light chain genes are protected against this process. Alternatively, PLL might be an heterogeneous disease with regard to the presence of somatic mutations.
Overall our results show that PLL cells, at least in some cases, resemble postgerminal center cells that have been selected by antigens. Whether some unidentified antigen plays a direct role in the development of the tumor remains to be elucidated. 10 For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
